Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:CASI NASDAQ:LPCN NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.55-2.2%$4.13$2.30▼$26.80$15.12M1.26344,699 shs37,256 shsCASICASI Pharmaceuticals$2.28-2.1%$1.70$1.09▼$7.67$28.04M0.77499,614 shs91,380 shsLPCNLipocine$2.89-0.3%$3.12$2.68▼$6.17$15.66M1.2832,963 shs16,254 shsSPRBSpruce Biosciences$8.15+9.0%$7.46$0.06▼$0.61$4.58M2.43802,052 shs7,050 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx-3.20%-1.36%-5.47%-31.12%-85.60%CASICASI Pharmaceuticals+1.30%+4.48%+19.49%+24.59%-64.15%LPCNLipocine0.00%-3.65%-7.35%-7.05%-20.55%SPRBSpruce Biosciences+6.86%-1.58%-8.50%+53.44%-77.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.55-2.2%$4.13$2.30▼$26.80$15.12M1.26344,699 shs37,256 shsCASICASI Pharmaceuticals$2.28-2.1%$1.70$1.09▼$7.67$28.04M0.77499,614 shs91,380 shsLPCNLipocine$2.89-0.3%$3.12$2.68▼$6.17$15.66M1.2832,963 shs16,254 shsSPRBSpruce Biosciences$8.15+9.0%$7.46$0.06▼$0.61$4.58M2.43802,052 shs7,050 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx-3.20%-1.36%-5.47%-31.12%-85.60%CASICASI Pharmaceuticals+1.30%+4.48%+19.49%+24.59%-64.15%LPCNLipocine0.00%-3.65%-7.35%-7.05%-20.55%SPRBSpruce Biosciences+6.86%-1.58%-8.50%+53.44%-77.95%Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.52N/AN/A$4.71 per share0.75CASICASI Pharmaceuticals$28.54M0.98N/AN/A$0.12 per share19.00LPCNLipocine$11.20M1.40N/AN/A$3.16 per share0.91SPRBSpruce Biosciences$4.91M0.93N/AN/A$1.88 per share4.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-45.34%-49.74%-17.54%N/ACASICASI Pharmaceuticals-$39.26M-$2.89N/A∞N/A-148.55%-1,844.13%-88.97%11/12/2025 (Estimated)LPCNLipocine$10K-$0.87N/A∞N/AN/A-23.59%-21.91%11/6/2025 (Estimated)SPRBSpruce Biosciences-$47.92M-$99.25N/AN/AN/A-555.23%-62.10%-47.49%11/10/2025 (Estimated)Latest SPRB, LPCN, CASI, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/29/2025Q2 2025CASICASI Pharmaceuticals-$0.47-$0.86-$0.39-$0.86$6.28 million$4.18 million8/14/2025Q2 2025BLRXBioLineRx-$0.35-$1.00-$0.65-$1.00$0.66 million$0.30 million8/5/2025Q2 2025LPCNLipocine-$0.41-$0.41N/A-$0.41$1.00 million$0.62 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/ACASICASI PharmaceuticalsN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.332.061.87CASICASI PharmaceuticalsN/A0.810.68LPCNLipocineN/A12.7112.71SPRBSpruce Biosciences0.015.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%CASICASI Pharmaceuticals22.23%LPCNLipocine9.11%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%CASICASI Pharmaceuticals21.24%LPCNLipocine6.35%SPRBSpruce Biosciences6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.26 million4.22 millionOptionableCASICASI Pharmaceuticals18012.30 million9.69 millionOptionableLPCNLipocine105.42 million5.08 millionNo DataSPRBSpruce Biosciences20562,00037.54 millionOptionableSPRB, LPCN, CASI, and BLRX HeadlinesRecent News About These CompaniesHead to Head Contrast: Spruce Biosciences (NASDAQ:SPRB) & MusclePharm (OTCMKTS:MSLP)August 24, 2025 | americanbankingnews.comSpruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesAugust 14, 2025 | businesswire.comSpruce Biosciences to enact 1-for-75 reverse stock splitJuly 24, 2025 | msn.comSpruce Biosciences Announces Reverse Stock SplitJuly 24, 2025 | finance.yahoo.comHMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive DisorderJuly 22, 2025 | globenewswire.comSPRB Spruce Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comSpruce Biosciences gets conditional approval to resume trading on Nasdaq Capital MarketJune 13, 2025 | msn.comSpruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital MarketJune 12, 2025 | finance.yahoo.comSpruce Biosciences’ Compliance Plan Accepted by NasdaqJune 12, 2025 | tipranks.comSpruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacksMay 7, 2025 | investing.comSpruce Biosciences Inc Ordinary SharesMay 6, 2025 | morningstar.comMSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 6, 2025 | finance.yahoo.comSpruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease AssetApril 28, 2025 | biospace.comBSpruce halves head count, narrowing focus to get ex-BioMarin drug to FDAApril 28, 2025 | fiercebiotech.comFSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17, 2025 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17, 2025 | insidermonkey.comSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)April 15, 2025 | standard-journal.comSWith BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15, 2025 | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15, 2025 | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025An Atomic Sized Surge Is Brewing for NuScale Power Stock PriceBy Thomas Hughes | August 11, 2025RSI Stock Soars 22% On Q2 Blowout—Will PENN Match the Momentum?By Nathan Reiff | August 7, 2025SPRB, LPCN, CASI, and BLRX Company DescriptionsBioLineRx NASDAQ:BLRX$3.55 -0.08 (-2.20%) Closing price 03:59 PM EasternExtended Trading$3.55 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.CASI Pharmaceuticals NASDAQ:CASI$2.28 -0.05 (-2.15%) Closing price 04:00 PM EasternExtended Trading$2.26 -0.02 (-0.88%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.Lipocine NASDAQ:LPCN$2.89 -0.01 (-0.34%) Closing price 03:59 PM EasternExtended Trading$2.90 +0.01 (+0.35%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Spruce Biosciences NASDAQ:SPRB$8.15 +0.67 (+8.96%) As of 09/3/2025Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Insider Selling: Risk Signal or Normal Activity? Gold’s Explosive Rally: GDX ETF May Be the Fast Track to Profits Dollar Tree Plunges Into Buy-Zone: A Robust Rebound Is Expected Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Ambarella's Earnings Prove Its Edge AI Strategy Is a Winner Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
